Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.79 |
| ▸ | DCUN1D1 | Q96GG9 | 11/20 | 0.67 |
| ▸ | UBE2M | P61081 | 9/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 2/20 | 0.60 |
| ▸ | HTT | P42858 | 2/20 | 0.60 |
| ▸ | XBP1 | P17861 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | KIT | P10721 | 1/20 | 0.57 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4282043 | 1.00 | EPHX2 (0.79) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL11417956 | 0.95 | EPHX2 (0.87) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL2752512 | 0.89 | EPHX2 (0.97) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL10943481 | 0.88 | EPHX2 (1.00) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL3956820 | 0.86 | EPHX2 (0.77) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL16570428 | 0.85 | EPHX2 (0.72) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL18658205 | 0.84 | EPHX2 (0.79) | EPHX2DCUN1D1UBE2MMEN1KMT2A | |
| SCHEMBL12474988 | 0.83 | EPHX2 (0.66) | EPHX2 | |
| SCHEMBL12474990 | 0.83 | EPHX2 (0.66) | EPHX2 | |
| SCHEMBL11311244 | 0.83 | EPHX2 (0.69) | EPHX2DCUN1D1UBE2MMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-05-28 | — | — | US | disclosed |
| EP-1904498-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| WO-2007004749-A1 | FUSED HETEROCYCLIC DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090137580-A1 | Fused Heterocyclic Derivatives and Use Thereof | TIE1, KDR, FLT1 | EPHX2 397/4885DCUN1D1 3560/4885UBE2M 1927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.